ReVeRa-201
Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray for the Reduction of Ventricular Rate in Patients with Atrial Fibrillation
- Stage
- klaar
- Medicine
- Etripamil
- Population
- Ritme
- Phase
- II
- First Patient In
- 6 February 2023
- Last Patient In
- 4 August 2023
- Last Patient Last Visit
- 31 December 2023
National Lead
dr. A.M.W. Alings
Cardioloog
Study Director
dr. M.E.W. Hemels
Cardioloog
Office Contact
